Syndax Pharmaceuticals, Inc.
SNDX
$18.79
-$0.33-1.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.89% | -26.85% | -37.64% | -52.25% | -68.71% |
| Total Depreciation and Amortization | -72.73% | -83.33% | -58.33% | -33.33% | -8.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.40% | 67.21% | 62.53% | 80.89% | 85.00% |
| Change in Net Operating Assets | -433.83% | -514.04% | -22.43% | -58.35% | -38.98% |
| Cash from Operations | -20.09% | -25.49% | -39.82% | -71.17% | -82.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -283.49% | -232.54% | -1,438.65% | -286.87% | 982.25% |
| Cash from Investing | -283.89% | -232.54% | -1,438.65% | -286.87% | 982.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.64% | -96.83% | -96.79% | -96.32% | 56.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 34.32% | 33.75% | 33.47% | 33.78% | 56.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -142.14% | -60.10% | -31.16% | -163.90% | 65.28% |